Merck KGaA to Close Merck Serono Site in Geneva, Cut Jobs
This article is for subscribers only.
Merck KGaA plans to close the Geneva headquarters of its Serono unit, five years after buying Europe’s biggest biotechnology company for about $13.3 billion to expand a drug business that has since faced development and regulatory setbacks.
Merck plans to transfer 750 positions to other locations, the Darmstadt, Germany-based company said in a statement today. Merck expects to cut 500 jobs in Geneva as well as 80 positions across three manufacturing sites in Switzerland, according to the statement.